Table Of Content

SUREPTECT CH DEX. reo : VOL 25" Me's). 6 & Brachytherapy (for prostate cancer), 165-178 Clinical results, 173-176 Adjuvant systemic primary breast cancer therapy, Historical background, 166 199-226. See also Breast cancer Isotopes, 169-172 Benefit evaluation, 200-203 Methods, generally, 166-167 Candidates for, 216-221 Overview, 165-166 Chemotherapy and radiation therapy sequencing, Retropubic technique, 167-168 214-215 Temporary implantation, 169 Chemotherapy dose intensity, 214 Transperineal technique, 168-169 Chemotherapy toxicity, 215-216 Chemotherapy trial results, 205 Breast cancer Combined hormone and chemotherapy, 211-213 Adjuvant systemic primary breast cancer therapy, Duration factors, 209-211 199-226 Hormone therapy , 211, 215 Ductal carcinoma in situ, 244-253 Immunotherapy, 213-214 The Foremost Cancer—Revisited, 197-198 (Editorial) Investigation areas, 221-222 Perspectives on Cancer Prevention, 5-7 Optimal chemotherapy regimens, 206 (Guest Editorial) Ovarian ablation trial results, 204 Primary chemotherapy in surgically resectable breast Overview, 199-200 cancer, 227-243 Primary invasive breast cancer surgery, recurrence Primary invasive breast cancer surgery, 279-288 factors, 285 Putting Prophylactic Mastectomy in Proper Tamoxifen benefits, 216 Perspective, 261-262 (Guest Editorial) Tamoxifen trial results, 204 Breast cancer patient advocacy, 114-126 World overview of trials, generally, 203-204 Adjuvant therapy, 120-121 Alcohol consumption Employment and insurance problems, 122-124 Oral and oropharyngeal squamous cancers, Issues, generally, 115-118, 123 329-332 Overview, 114 Patient-physician communication, 118-119 American Cancer Society Primary treatment choice, 119-120 Acknowledgment 1993-1994, 112-113 Providers involved in, 124 Acknowledgment 1995, 377 Psychosocial issues, 121-122 Cervical cancer early detection guidelines, 314 Rationale, 115 Clinical Awards, 192 Reconstructive surgery, 120 Clinical Oncology Social Work Training Grants, 256 Cytotechnology Training Grants, 147 Breast cancer risk evaluation and management, 263- Highlights of National Conference on Gynecologic 278 Cancers, 254-255 Current approach, 275-276 National Conference on Colorectal Cancer, 256 Overview, 263 Prophylactic mastectomy, 268-275 Announcements Risk factors, 263-268 American Cancer Society Clinical Awards, 192 American Cancer Society Cytotechnology Training Breast reconstruction, 289-304 Grants, 147 Breast cancer patient advocacy, 119, 120 International Union Against Cancer World Implants, 293-295 Conference for Cancer Organisations, 243, 376 Management team, 290 Overview, 289-290 Anthracyclines Reach to Recovery Program, 290 Adjuvant systemic primary breast cancer therapy, 206- Techniques, 295-303 209 Timing and selection, 291-293 Assay variability Treatment role, 290-291 Prostate-specific antigen (PSA), 160-161 Breast self-examination Axillary lymph nodes Prophylactic mastectomy alternatives, 273 Primary invasive breast cancer surgery, 285-286 Cc California Tobacco Control Program, 369-372 Bilateral salpingo-oophorectomy Epithelial ovarian cancer metastasis, 89 Cancer Statistics, 8-30 Incidence, 11, 12, 14, 16 Biopsy Mornality, 11, 13, 15, 17, 18-24, 28-29 Oral and oropharyngeal squamous cancers, Overview, 8-10 348-349 Stage at diagnosis, 26 Prostate-specific antigen (PSA) screening, 161 Survival rates, 25, 27, 30 378 CA—A CANCER JOURNAL FOR CLINICIANS SUREPTECT CH DEX. reo : VOL 25" Me's). 6 & Brachytherapy (for prostate cancer), 165-178 Clinical results, 173-176 Adjuvant systemic primary breast cancer therapy, Historical background, 166 199-226. See also Breast cancer Isotopes, 169-172 Benefit evaluation, 200-203 Methods, generally, 166-167 Candidates for, 216-221 Overview, 165-166 Chemotherapy and radiation therapy sequencing, Retropubic technique, 167-168 214-215 Temporary implantation, 169 Chemotherapy dose intensity, 214 Transperineal technique, 168-169 Chemotherapy toxicity, 215-216 Chemotherapy trial results, 205 Breast cancer Combined hormone and chemotherapy, 211-213 Adjuvant systemic primary breast cancer therapy, Duration factors, 209-211 199-226 Hormone therapy , 211, 215 Ductal carcinoma in situ, 244-253 Immunotherapy, 213-214 The Foremost Cancer—Revisited, 197-198 (Editorial) Investigation areas, 221-222 Perspectives on Cancer Prevention, 5-7 Optimal chemotherapy regimens, 206 (Guest Editorial) Ovarian ablation trial results, 204 Primary chemotherapy in surgically resectable breast Overview, 199-200 cancer, 227-243 Primary invasive breast cancer surgery, recurrence Primary invasive breast cancer surgery, 279-288 factors, 285 Putting Prophylactic Mastectomy in Proper Tamoxifen benefits, 216 Perspective, 261-262 (Guest Editorial) Tamoxifen trial results, 204 Breast cancer patient advocacy, 114-126 World overview of trials, generally, 203-204 Adjuvant therapy, 120-121 Alcohol consumption Employment and insurance problems, 122-124 Oral and oropharyngeal squamous cancers, Issues, generally, 115-118, 123 329-332 Overview, 114 Patient-physician communication, 118-119 American Cancer Society Primary treatment choice, 119-120 Acknowledgment 1993-1994, 112-113 Providers involved in, 124 Acknowledgment 1995, 377 Psychosocial issues, 121-122 Cervical cancer early detection guidelines, 314 Rationale, 115 Clinical Awards, 192 Reconstructive surgery, 120 Clinical Oncology Social Work Training Grants, 256 Cytotechnology Training Grants, 147 Breast cancer risk evaluation and management, 263- Highlights of National Conference on Gynecologic 278 Cancers, 254-255 Current approach, 275-276 National Conference on Colorectal Cancer, 256 Overview, 263 Prophylactic mastectomy, 268-275 Announcements Risk factors, 263-268 American Cancer Society Clinical Awards, 192 American Cancer Society Cytotechnology Training Breast reconstruction, 289-304 Grants, 147 Breast cancer patient advocacy, 119, 120 International Union Against Cancer World Implants, 293-295 Conference for Cancer Organisations, 243, 376 Management team, 290 Overview, 289-290 Anthracyclines Reach to Recovery Program, 290 Adjuvant systemic primary breast cancer therapy, 206- Techniques, 295-303 209 Timing and selection, 291-293 Assay variability Treatment role, 290-291 Prostate-specific antigen (PSA), 160-161 Breast self-examination Axillary lymph nodes Prophylactic mastectomy alternatives, 273 Primary invasive breast cancer surgery, 285-286 Cc California Tobacco Control Program, 369-372 Bilateral salpingo-oophorectomy Epithelial ovarian cancer metastasis, 89 Cancer Statistics, 8-30 Incidence, 11, 12, 14, 16 Biopsy Mornality, 11, 13, 15, 17, 18-24, 28-29 Oral and oropharyngeal squamous cancers, Overview, 8-10 348-349 Stage at diagnosis, 26 Prostate-specific antigen (PSA) screening, 161 Survival rates, 25, 27, 30 378 CA—A CANCER JOURNAL FOR CLINICIANS SUBJECT INDEX tS33+ Vt £5 NOS.1-6 Cervical cancer Cryosurgery Papanicolaou smear, 305-320 Colorectal liver metastases, 56-58 Cervical esophagus Cyclophosphamide Head and neck cancer treatment, 360-361 Adjuvant systemic primary breast cancer therapy, 205, 207, 209 Cervical lymph nodes Epithelial ovarian cancer treatment, 92-95, 98 Head and neck cancer, 354, 363-364 Primary chemotherapy in surgically resectable breast Chemoprevention, 31-49 cancer, 229 Agents, 32-33, 38, 39 Biomarkers, 40-41 Future trends, 46-47 Genetic mechanism targeting, 33, 36-37 Group targeting, 46 Digital rectal examination (DRE) NCI program, 37-40 Prostate cancer screening, 137, 138, 139, 150 Overview, 31-32 Doxorubicin Trials, 34-35, 41-46 Adjuvant systemic primary breast cancer therapy, Chemotherapy 206, 207, 209 Adjuvant systemic primary breast cancer therapy, Epithelial ovarian cancer treatment, 94, 95 205, 206 Adjuvant systemic primary breast cancer therapy, Ductal carcinoma in situ, 244-253 combined hormone therapy, 211-213 Future studies, 252 Adjuvant systemic primary breast cancer therapy, Malignant potential, 246-247 dose intensity, 214 Management approach, 250-251 Adjuvant systemic primary breast cancer therapy, Overview, 244 radiation therapy sequencing, 214-215 Pathology, 245-246 Colorectal metastases to liver, 51, 53, 56, 57 Presentation, 244-245 Epithelial ovarian cancer treatment, 91-99 Treatment options, 247-250 Primary, in surgically resectable breast cancer, Treatment recommendations, 251-252 227-243 Dysplasia Chiorambucil Oral and oropharyngeal squamous cancers, Epithelial ovarian cancer treatment, 92, 94 341-343 Cigarette smoking Oral and oropharyngeal squamous cancers, 329-332 Perspectives on Cancer Prevention, 5-7 (Guest Editorial) Tobacco use prevention and cessation, 369-374 Early Diagnosis and Treatment of Head and Neck Cancer, 325-327 (Guest Editorial) Cisplatin Head and neck cancer, 353 Epithelial ovarian cancer treatment, 91-95 Oral and oropharyngeal squamous cancers, Primary chemotherapy in surgically resectable breast 328-351 cancer, 230 Ovarian cancer, 71-87 Clinical breast examination Papanicolaou smear, 305-320 Prophylactic mastectomy alternatives, 273-275 Prostate cancer screening, 134-147 Prostate-specific antigen (PSA), 148-164 Colorectal cancer AJCC report, 107 Editorials Genetics, 36, 37 Early Diagnosis and Treatment of Head and Neck Perspectives on Cancer Prevention, 6 Cancer, 325-327(Guest Editorial) (Guest Editorial) The Foremost Cancer—Revisited, 197-198 Ovarian Cancer, 69-70 (Guest Editorial) Colorectal liver metastases, 50-62 Perspectives on Cancer Prevention, 5-7 Cryosurgery, 56-58 (Guest Editorial) Medical treatment, 51, 53 Prostate Cancer: Here and Now, 133 Natural history, 50-51, 52 Putting Prophylactic Mastectomy in Proper Overview, 50 Perspective, 261-262 (Guest Editorial) Regional infusion therapy, 58-60 Surgical resection, 51-52, 54-56 Employment problems Vascular interruption, 60 Breast cancer patient advocacy, 122-124 Combined hormone and chemotherapy Epidemiology Adjuvant systemic primary breast cancer therapy, Cancer statistics, 8-30 211-213 Prostate cancer screening, 142-145 VOL. 45 NO. 6 NOVEMBER/DECEMBER 1995 SUBJECT INDEX. Loos: VOL 45. NOS .1-¢6 Epirubici Glisson’s capsule Adjuvant systemic primary breast cancer therapy, 206 Epithelial ovarian cancer metastasis, 88, 89 Epithelial ovarian cancer treatment, 94 Gluteus maximus musculocutaneous flap Primary chemotherapy in surgically resectable breast breast reconstruction techniques, 302-303 cancer, 230, 231 Epithelial ovarian cancer H Advanced-stage disease, 93-99 Early-stage disease, 89, 91-93 Head and neck cancer Epithelial ovarian cancer treatment, 88-101 Cervical lymph node management, 363-364 Ovarian cancer detection, 73 Cervical lymph nodes, 354 Overview, 88 Clinical diagnosis, 353 Surgery and staging, 88-89 Early Diagnosis and Treatment of Head and Neck Errata Cancer, 325-327 (Guest Editorial) Cancer Statistics, 1995, 127-128 Follow-up care and prevention, 365-366 Larynx, hypopharynx, and cervical esophagus Erythroplasia treatment, 360-361 Oral and oropharyngeal squamous cancers, Oral and oropharyngeal squamous cancers, 336-338 early detection, 328-351 Esophageal cancer Oral cavity treatment, 358-359 Head and neck cancer treatment, 360-361 Overview, 352-353 Risk factors, 329 Paranasal sinus treatment, 361-363 Pharynx treatment, 359-360 Etoposide Radiation therapy, 364-365 Epithelial ovarian cancer treatment, 94, 95 Reconstruction and rehabilitation, 365 Extensive intraductal component Salivary gland treatment, 363 Primary invasive breast cancer surgery, recurrence Staging, 354-355 factors, 284 Treatment alternatives, 356 Treatment goals, 355-356 Treatment selection, 356-358 F Health insurance Breast cancer patient advocacy, 122-124 Familial cancer Perspectives on Cancer Prevention, 5-7 Hepatic artery infusional (HAI) chemotherapy (Guest Editorial) Colorectal metastases to liver, 56, 59 Family history Hepatic artery ligation (HAL) Breast cancer risk evaluation, 264 Colorectal liver metastases, 60 Ovarian cancer detection, 75 Hexamethylmelamine Fertility Epithelial ovarian cancer treatment, 94, 95 Breast cancer patient advocacy, 121 Hormone therapy Fibrocystic disease Adjuvant systemic primary breast cancer therapy, 211 Breast cancer risk evaluation, 267 Adjuvant systemic primary breast cancer therapy, combined chemotherapy, 211-213 Finasteride Adjuvant systemic primary breast cancer therapy, Chemoprevention, 33 toxicity, 211-213 5-Fluorouracil (5-FU) Chemoprevention, 33 Adjuvant systemic primary breast cancer therapy, Prostate cancer, 166 205, 209 Prostate cancer screening, 137 Colorectal metastases to liver, 51 Hypopharynx Epithelial ovarian cancer treatment, 94, 95 Head and neck cancer treatment, 360-361 Primary chemotherapy in surgically resectable breast cancer, 229, 230 G Ifosfamide Epithelial ovarian cancer treatment, 95-96 Genetics Immunotherapy Breast cancer risk evaluation, 264-266 Adjuvant systemic primary breast cancer therapy, 213 Chemoprevention, 33, 36-37 Ovarian cancer, 69-70 (Guest Editorial) Implants Ovarian cancer detection, 75-76, 79-80 Breast reconstruction, 293-295 CA—A CANCER JOURNAL FOR CLINICIANS SUBJECT INDEX. oo S: ViGi 45. NOS .13-6 Intraperitoneal chemotherapy Mitcomycin Epithelial ovarian cancer treatment, 96-97 Epithelial ovarian cancer treatment, 94 Primary chemotherapy in surgically resectable breast cancer, 231 L Mitoxantrone Epithelial ovarian cancer treatment, 94 Modified radical mastectomy Head and neck cancer treatment, 360-361 Breast cancer patient advocacy, 119 Latissimus dorsi musculocutaneous flap Breast reconstruction techniques, 302 Molecular biomarkers Ovarian cancer detection, 79-80, 81 Leucovorin MYCN oncogene amplification Colorectal metastases to liver, 51 Neuroblastoma, 180 Leukoplakia Oral and oropharyngeal squamous cancers, Myelosuppression Epithelial ovarian cancer treatment, 95 338-34] Liver metastatic disease Colorectal metastases to liver, 50-62 Lobular carcinoma in situ The National Cancer Data Base clinical highlights, Breast cancer risk evaluation, 267 102-111 Breast cancer, 108 Low malignant potential (LMP) tumor Characteristics, 104-105 Ovarian cancer detection, 73, 74 Colorectal cancer, 107 Lung cancer Data presentation, 106 Genetics, 36 Data sources, 102-103, 106 Perspectives on Cancer Prevention, 5-7 Laryngeal cancer, 109 (Guest Editorial) Overview, 102 Lymph nodes Pancreatic cancer, 111 Epithelial ovarian cancer metastasis, 88, 89 Prostate cancer, 110 Thyroid cancer, 11 Head and neck cancer, 354, 363-364 Primary invasive breast cancer surgery, recurrence Neuroblastoma, 179-192 factors, 283 Disease sites, 182-183 Epidemiology, 179-180 Evaluation, 183-184 Overview, 179 Pathophysiology, 180-182 Mammography Prognostic factors, 185 Prophylactic mastectomy alternatives, 273-275 Signs and symptoms, 182 Staging, 184-185 Mastectomy Treatment, 185-189 Breast cancer patient advocacy, 119 Breast reconstruction, 289-304 Nipple-areola reconstruction Breast reconstruction techniques, 303 Ductal carcinoma in situ, 247-250 Primary invasive breast cancer surgery, 279-288 Nutrition and diet Putting Prophylactic Mastectomy in Proper Chemoprevention, 31-33, 43-45 Perspective, 261-262 (Guest Editorial) Perspectives on Cancer Prevention, 5-7 Melphalan (Guest Editorial) Adjuvant systemic primary breast cancer therapy, 205 Epithelial ovarian cancer treatment, 91, 92, 94 Oo Metastatic disease Oral and oropharyngeal squamous cancers, Adjuvant systemic primary breast cancer therapy, 206 328-351 Breast cancer, primary chemotherapy, 227, 228 Biopsy, 348-349 Colorectal metastases to liver, 50-62 Dysplasia, carcinoma-in-situ and invasive Epithelial ovarian cancer, 88, 89 carcinoma, 341-343 Methotrexate Erythroplasia, 336-338 Adjuvant systemic primary breast cancer therapy, 205 Intraoral examination, 335-336 Epithelial ovarian cancer treatment, 94 Lesion workup, 348 Primary chemotherapy in surgically resectable breast Leukoplakia, 338-341 cancer, 229, 231 Overview, 328-329 VOL. 45 NO. 6 NOVEMBER/DECEMBER 1995 Poepyecsi:. TM DER, PISS VOd £5. WO's 1-6 Risk factors, 329-332 Primary chemotherapy in surgically resectable Risk sites, 332-334 breast cancer, 229 Staging, 343-344 Pregnancy Vital staining, 345-348 Breast cancer risk evaluation, 266 Oral cavity Prevention Head and neck cancer treatment, 358-359 Perspectives on Cancer Prevention, 5-7 Orchiectomy (Guest Editorial) Prostate cancer, 166 Primary chemotherapy in surgically resectable breast Ovarian ablation cancer, 227-243. See also Breast cancer Adjuvant systemic primary breast cancer therapy, 204 Background, 228-229 Chemotherapy and radiation therapy sequence, Ovarian Cancer, 69-70 (Guest Editorial) 240-241 Ovarian cancer detection, 71-87 Early clinical trials, 229-232 Biochemical markers, 77-79 Experimental basis, 227-228 Biostatistical considerations, 74-75 Milan Cancer Institute trials, 232-235 Clinical applications, 80-83 Overview, 227 Imaging modalities, 76-77 Recent randomized trials, 235-237 Molecular biomarkers, 79-80, 81 Surgical management selection, 237-240 Overview, 71-73 Primary invasive breast cancer surgery, 279-288 Pathologic entity, 73-74 Axillary lymph nodes, 285-286 Patient history and physical examination, 75-76 Breast-conserving treatment, 280-281 Ovarian cancer treatment. See Epithelial Contraindications, 281 ovarian cancer Overview, 279 Radiation therapy, 280-281 Pp Recurrence factors, 281-285 Survival for early-stage cancer, 279-280 Paclitaxel Prophylactic mastectomy. See also Breast cancer Epithelial ovarian cancer treatment (advanced stage), Alternatives to, 273-275 94, 96-99 Generally, 268-270 Pancreatic cancer Indications for, 271-273 Genetics, 36 Putting Prophylactic Mastectomy in Proper Perspective, 261-262 (Guest Editorial) Papanicolaou smear, 305-320 Technique, 270-271 Accuracy of, 310-311 Adequacy of, 309-310 Prostate cancer Atypical cells, 307-309 Brachytherapy, 165-178 Automation of, 312-313 Chemoprevention, 33, 43 Clinical considerations, 315 Prostate Cancer: Here and Now, 133 (Editorial) Cytologic nomenclature, 306-307 Prostate cancer screening, 134-147 Economic factors, 317-318 Epidemiologic evidence supporting, 142-145 Human resources for, 312 Evidence supporting, generally, 138-139 Management guidelines, 315-316 Overview, 134-135 Medicolegal/CLIA aspects, 316-317 Pathologic evidence supporting, 139-142 Overview, 305-306 Prostate-specific antigen (PSA), 148-164 Screening guidelines and intervals, 313-315 Rationale, 135-138 Paranasal sinus Prostate-specific antigen (PSA), 148-164 Head and neck cancer treatment, 361-363 Assay variability, 160-161 Patient-physician communication Background, 148-149 Breast cancer patient advocacy, 118-119 Digital rectal examination (DRE) and, 150 Issues, 161-162 Pharynx Overview, 148 Head and neck cancer treatment, 359-360 Prostate cancer screening, 135, 137, 138, 139 Ploidy Repeat biopsy requirement, 161 Specificity enhancement, 150-160 Neuroblastoma, 180 Standardization, 161 Postmenopausal palpable ovary syndrome Strategy evaluation, 149-150 Ovarian cancer detection, 75 Psychosocial issues Prednisone Breast cancer patient advocacy, 121-122 Adjuvant systemic primary breast cancer therapy, 205 CA—A CANCER JOURNAL FOR CLINICIANS SUBJECT tnNDEX. PI23 3: Vat 23>. Was .1-6 Colorectal metastases to liver, 50-62 Ductal carcinoma in situ, 247-250 Radiation therapy Epithelial ovarian cancer treatment, 88-89 Adjuvant systemic primary breast cancer therapy, Head and neck cancer, 358-365 chemotherapy therapy sequencing, 214-215 Primary invasive breast cancer, 279-288 Breast cancer patient advocacy, 120 Prophylactic mastectomy, 270-275 Ductal carcinoma in situ, 247-250 Putting Prophylactic Mastectomy in Proper Epithelial ovarian cancer treatment, 91, 92 Perspective, 261-262 (Guest Editorial) Head and neck cancer, 364-365 Primary chemotherapy in surgically resectable breast cancer, 240-241 , a Primary invasive breast cancer surgery, 280-281 Prostate cancer, 165-178. See also Brachytherapy Tamoxifen Prostate cancer screening, 137 Adjuvant systemic primary breast cancer therapy, Radical mastectomy 204, 216 Challenges to, 200 Chemoprevention, 33 Epithelial ovarian cancer treatment, 94 Radical prostatectomy Primary chemotherapy in surgically resectable breast Prostate cancer, 137, 166 cancer, 229 Reach to Recovery Program Prophylactic mastectomy alternatives, 275 Breast reconstruction, 290 Taxotere Recurrence fears Epithelial ovarian cancer treatment, 94 Breast cancer patient advocacy, 122 Thrombocytopenia Regional infusion therapy Epithelial ovarian cancer treatment, 95 Colorectal liver metastases, 58-60 Tobacco use prevention and cessation, 369-374 Retroperitoneal lymph nodes California Tobacco Control Program, 369-372 Epithelial ovarian cancer metastasis, 88 Overview, 369 Primary care physician role, 372-373 Retropubic technique Brachytherapy (for prostate cancer), 167-168 Toxicity Adjuvant systemic primary breast cancer therapy, chemotherapy, 215-216 S Adjuvant systemic primary breast cancer therapy, hormone therapy, 211-213 Salivary gland treatment Head and neck cancer, 363 Transabdominal and transvaginal sonography Ovarian cancer detection, 76-77 Salvage chemotherapy Epithelial ovarian cancer treatment Transperineal technique (advanced stage), 95-96 Brachytherapy (for prostate cancer), 168-169 Sexual functioning Transrectal ultrasound (TRUS) Breast cancer patient advocacy, 121-122 Prostate cancer screening, 137, 138, 139, 154-155, 167 Sonography Transverse retus abdominis musculocutaneous Ovarian cancer detection, 76-77 (TRAM) flap Transrectal ultrasound (TRUS), prostate cancer Breast reconstruction techniques, 301-302 screening, 137, 138, 139, 154-155, 167 Staging V Chemoprevention, 37 Epithelial ovarian cancer treatment, 88-89, 90 Vascular interruption Head and neck cancer, 354-355 Colorectal liver metastases, 60 Neuroblastoma, 184-185 Oral and oropharyngeal squamous cancers, Vinblastin 343-345 Primary chemotherapy in surgically resectable Ovarian cancer, 69 (Guest Editorial), 71, 72 breast cancer, 229 Statistics, See Cancer Statistics Vincristine Primary chemotherapy in surgically resectable Surgical management breast cancer, 231 Brachytherapy, 166 Breast cancer, primary chemotherapy in surgically Vital staining resectable breast cancer, 227-243 Oral and oropharyngeal squamous cancers, Breast reconstruction, 289-304 VOL. 45 NO. 6 NOVEMBER/DECEMBER 1995 AUTHOR tn DEX. 199s: VGt.°25.. NOS. Matthay KK, 179-192 McGuire WP, 88-101 Bal DG, 369-374 Menck HR, 102-111 Bilimoria MM, 263-278 Moore MP, 279-288 Blasko JC, 165-178 Morrow M, 244-253, 263-278 Blumgart LH, 50-62 Murphy GP, 102-111, 133 (Editorial) Bolden S, 8-30 Bonadonna G, 227-243 Oo Bostwick J III, 289-304 Brawer MK, 148-164 Ohori M, 134-147 Burch-Whitman C, 31-49 Pp Buzdar AU, 199-226 Cc Park RC, 71-87 Patrick RL, 305-320 Cherny NI, 64 (Letter) Petrek JA, 197-198 (Editorial) Cohen AM, 50-62 Portenoy RK, 64 (Letter) Porter AT, 165-178 Q Dillioglugil O, 134-147 Qazi F, 88-101 F Fong Y, 50-62 Ragde H, 165-178 G Reddy SM, 165-178 Ganz PA, 114-126 _ Garfinkel L, 5-7 (Guest Editorial) Greenwald P, 31-49 Salvadori B, 227-243 Grimm PD, 165-178 Samit A, 328-351 Scardino PT, 134-147 Hi Schnitt SJ, 244-253 Shah JP, 352-368 Harris JR, 244-253 Shingleton HM, 305-320 Hetelekidis S, 244-253 Slawin KM, 134-147 Holleb AI, 197-198 (Editorial) Smith RA, 305-320 Hortobagyi GN, 199-226 Steele GD Jr, 102-111 J Jessup LM, 102-111 Teneriello MG, 71-87 Johnston WW, 305-320 Tong T, 8-30 K V Kelloff G, 31-49 Valagussa P, 227-243 Kinne DW, 279-288 Kramer BS, 31-49 Ww L Winchester DP, 102-111, 261-262 (Guest Editorial) Wingo PA, 8-30 Lloyd JC, 369-374 Loré JM Jr, 325-327 (Guest Editorial) Y Lydiatt W, 352-368 Young RC, 69-70 (Guest Editorial) é ” Mangalik A, 63-64 (Letter) Manley MW, 369-374 Zucali R, 227-243 Mashberg A, 328-351 CA—A CANCER JOURNAL FOR CLINICIANS